Jardiance now gets FDA nod for chronic kidney disease

Adding to a list of indications for the blockbuster drug, the US Food and Drug Administration (FDA) on Friday approved Jardiance (empagliflozin) 10mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.

However, the med is not recommended for use with in patients who require intravenous immunosuppressive therapy or those with polycystic kidney disease.

Jardiance was developed by German family-owned pharma major Boehringer Ingelheim and is partnered with the USA’s Eli Lilly (NYSE: LLY). The SGLT blocker generated revenues of about $6.5 billion last year, nearly 40% more than its 2021 sales. Jardiance recently gained European and UK approval for the chronic kidney disease indication.